Company Profile
A Vancouver-based clinical-stage biotech designing next-generation serotonin-targeting drugs for serious psychiatric disorders — aiming to deliver psychedelic-like therapeutic benefits without the hallucinogenic experience.
Rank #8
DRUG
$76.51
+2.55% (24h)
Last updated: 1 second ago
Market Cap
$750.72M
Volume (24h)
50.46K
Last Close (7D)
$76.51
A Vancouver-based clinical-stage biotech designing next-generation serotonin-targeting drugs for serious psychiatric disorders — aiming to deliver psychedelic-like therapeutic benefits without the hallucinogenic experience.
52-Week Range